4D Molecular Therapeutics FDMT Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $72.49M-45.7% | $60.24M-59.7% | $48.56M-74.1% | $77.16M-59.2% | $133.53M-51.5% | ||
| $318.4M+69.4% | $342.41M+24.3% | $256.51M-18.4% | $216.07M-38.8% | $187.91M-24.9% | ||
| $14.47M+30.0% | $10.48M+4.2% | $7.31M-17.5% | $10.06M-5.8% | $11.13M+15.0% | ||
| $405.36M+21.9% | $413.13M-5.0% | $312.38M-38.8% | $303.29M-45.1% | $332.57M-37.9% | ||
| $13.59M-27.5% | $14.87M-23.9% | $16.15M-18.7% | $17.51M-6.7% | $18.75M-3.7% | ||
| $17.36M-14.8% | $18.14M-13.9% | $18.91M-13.1% | $19.65M+83.8% | $20.37M+83.2% | ||
| $9.86M+40.0% | $9.19M+116% | $9.38M+228% | $9.39M+305% | $7.04M+813% | ||
| $512.91M-0.5% | $566.71M+1.1% | $423.98M-29.8% | $473.64M-23.6% | $515.73M-18.1% | ||
| $14.69M+254% | $11.16M+154% | $6.86M+135% | $8.7M+154% | $4.15M-1.6% | ||
| $22.87M+41.1% | $26.87M+42.4% | $24.19M+13.0% | $19.19M+50.2% | $16.2M+79.8% | ||
| $360K-58.4% | $360K+40.1% | $360K+929% | $1.07M— | $866K— | ||
| $5.49M-3.4% | $5.59M-0.8% | $5.7M+11.9% | $5.72M+79.0% | $5.68M+79.0% | ||
| $2.13M+390% | $745K-29.5% | $835K-34.8% | $219K-83.4% | $434K-67.2% | ||
| $43.4M+61.4% | $43.99M+50.9% | $37.11M+25.9% | $34.68M+78.7% | $26.9M+64.0% | ||
| $15.05M-17.2% | $15.82M-16.6% | $16.57M-16.1% | $17.36M+65.9% | $18.17M+65.2% | ||
| $20.54M-13.9% | $21.41M-13.0% | $22.26M-10.4% | $23.08M+69.0% | $23.85M+68.3% | ||
| $121K-31.6% | $138K-28.5% | $144K-26.5% | $161K-24.8% | $177K-23.4% | ||
| $61.07M+32.7% | $61.05M+22.6% | $55M+7.7% | $52.75M+66.0% | $46.01M+56.9% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $5K0.0% | $6K+20.0% | $5K0.0% | $5K0.0% | $5K0.0% | ||
| $1.24B+13.1% | $1.22B+12.4% | $1.1B+2.4% | $1.1B+2.6% | $1.09B+4.3% | ||
| -$785.06M-25.8% | -$716.3M-24.3% | -$735.7M-39.7% | -$678.83M-40.6% | -$624.17M-39.4% | ||
| -$180K-154% | $727K+217% | $671K-37.8% | $337K+215% | $332K+405% | ||
| $451.84M-3.8% | $505.66M-1.0% | $368.98M-33.3% | $420.89M-28.5% | $469.72M-21.8% | ||
| $512.91M-0.5% | $566.71M+1.1% | $423.98M-29.8% | $473.64M-23.6% | $515.73M-18.1% | ||
| —— | —— | —— | —— | —— | ||
| $318.4M+69.4% | $342.41M+24.3% | $256.51M-18.4% | $216.07M-38.8% | $187.91M-24.9% | ||
| $9.86M+40.0% | $9.19M+116% | $9.38M+228% | $9.39M+305% | $7.04M+813% | ||
| $17.36M-14.8% | $18.14M-13.9% | $18.91M-13.1% | $19.65M+83.8% | $20.37M+83.2% | ||
| $17.36M-14.8% | $18.14M-13.9% | $18.91M-13.1% | $19.65M+83.8% | $20.37M+83.2% | ||
| $9.86M+40.0% | $9.19M+116% | $9.38M+228% | $9.39M+305% | $7.04M+813% | ||
| $17.36M-14.8% | $18.14M-13.9% | $18.91M-13.1% | $19.65M+83.8% | $20.37M+83.2% | ||
| $9.86M+40.0% | $9.19M+116% | $9.38M+228% | $9.39M+305% | $7.04M+813% | ||
| $2.13M+390% | $745K-29.5% | $835K-34.8% | $219K-83.4% | $434K-67.2% | ||
| $22.87M+41.1% | $26.87M+42.4% | $24.19M+13.0% | $19.19M+50.2% | $16.2M+79.8% | ||
| $22.87M+41.1% | $26.87M+42.4% | $24.19M+13.0% | $19.19M+50.2% | $16.2M+79.8% | ||
| $370K+14.9% | $358K-12.7% | $345K-12.9% | $334K-12.6% | $322K-12.7% | ||
| $2.13M+390% | $745K-29.5% | $835K-34.8% | $219K-83.4% | $434K-67.2% | ||
| $370K+14.9% | $358K-12.7% | $345K-12.9% | $334K-12.6% | $322K-12.7% | ||
| $2.13M+390% | $745K-29.5% | $835K-34.8% | $219K-83.4% | $434K-67.2% | ||
| $20.54M-13.9% | $21.41M-13.0% | $22.26M-10.4% | $23.08M+69.0% | $23.85M+68.3% | ||
| $1.24B+13.1% | $1.22B+12.4% | $1.1B+2.4% | $1.1B+2.6% | $1.09B+4.3% | ||
| $5K0.0% | $6K+20.0% | $5K0.0% | $5K0.0% | $5K0.0% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $370K+14.9% | $358K-12.7% | $345K-12.9% | $334K-12.6% | $322K-12.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are 4D Molecular Therapeutics's total assets?
- 4D Molecular Therapeutics (FDMT) holds $512.9M in total assets, down 0.5% year over year.
- How much debt does 4D Molecular Therapeutics have?
- 4D Molecular Therapeutics carries $20.5M in total debt against $451.8M of shareholders' equity, a debt-to-equity ratio of 0.05.
- How much cash does 4D Molecular Therapeutics have?
- 4D Molecular Therapeutics holds $72.5M in cash and equivalents.
- Can 4D Molecular Therapeutics cover its short-term obligations?
- Its current ratio is 9.34 — current assets exceed current liabilities.
- Where does 4D Molecular Therapeutics's balance sheet data come from?
- Every line is extracted from 4D Molecular Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
